Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 58, Issue SUPPL. 1, 1999, Pages

  Maini, R N ^a,b   Taylor, P C ^a   Paleolog, E ^a   Charles, P ^a   Ballara, S ^a   Brennan, F M ^a   Feldmann, M ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; BLOCKING AGENT; INFLIXIMAB; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ANGIOGENESIS; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG SCREENING; HUMAN; IMMUNOPATHOGENESIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0032705588     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.58.2008.i56     Document Type: Review

References (14)

1. Feldmann M, Bondeson J, Brennan FM, Foxwell BMJ, Maini RN. The rationale for the current boom in anti-TNFα treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFα and minimise hazards? Ann Rheum Dis 1999;58:(Suppl 1)127-131.
2. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 1993; 36:1681-90.
3. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
4. Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors and acute phase proteins following anti-TNFα therapy in rheumatoid arthritis. J Immunol 1999;163:1521-8.
5. Lorenz HM, Antoni C, Valerius T, et al. In vivo blockade of TNF-α by intravenous infusion of a chimeric monoclonal TNF-α antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. J Immunol 1996; 156:1646-53.
6. Taylor PC, Chapman P, Ellioit MJ, et al. TNFα blockade in patients with rheumatoid reduces granulocyte margination and traffic to joints with concomitant reduction in synovial chemotactic gradients. [Abstract]. Clin Exp Rheumatol 1998;16:204.
7. Tak PP, Taylor PC, Breedveld FC, et al. Decrease in cellularity and expression of adhesion molecules in rheumatoid synovial tissue after anti-TNFα monoclonal antibody treatment. Arthritis Rheum 1996;39:1077-81.
8. Paleolog EM, Hunt M, Elliott MJ, Woody JN, Feldmann M, Maini RN. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor α antibody in rheumatoid arthritis. Arthritis Rheum 1996;39:1082-91.
9. Taylor PC, Chapman P, Elliott MJ, et al. Reduced granulocyte traffic and chemotactic gradients in rheumatoid joints following anti-TNF-α antibody therapy. Arthritis Rheum (in press).
10. Ballara S, Taylor PC, Paleolog E, Feldmann M, Maini RN. TNFα blockade in rheumatoid arthritis reduces synovial vascularity. [Abstract]. Scand J Immunol 1999;49:333.
11. Paleolog EM, Young S, Stark AC, et al. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor α and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 1998;41:1258-65.
12. Williams RO, Feldmann M, Maini RN. Anti-Tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Nat Acad Sci USA 1992;89: 9784-8.
13. Brennan FM, Browne KA, Green PA, Jaspar J-M, Maini RN, Feldmann M. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-α (cA2) therapy. Br J Rheumatol 1997;36:643-50.
14. Brennan FM, Chantry D, Jackson A, Maini RN, Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;2:244-7.